GlassScriptPhysician profile
Charles H Rheeman
NPI 1073572236
$50,416.61
in general payments reported to CMS, 2019-2025
27 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $452 · 2021: $1,392 · 2022: $4,146 · 2023: $2,148 · 2024: $27K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $8,777 · Travel and Lodging: $1,504 · Honoraria: $400 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,090.00 |
| Food and Beverage | $8,777.20 |
| Travel and Lodging | $1,503.53 |
| Honoraria | $400.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37,422.73 | 2024-2025 | Uplizna, Tepezza |
| Horizon Therapeutics Plc | $5,203.04 | 2020-2023 | Uplizna, Tepezza |
| Mallinckrodt Hospital Products INC. | $3,129.55 | 2020-2025 | Acthar |
| Bausch & Lomb Americas INC. | $1,226.36 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $514.08 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $433.02 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $377.73 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $326.45 | 2019-2021 | |
| Alcon Vision LLC | $263.09 | 2022-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Allergan, INC. | $222.57 | 2019 | |
| Astellas Pharma US INC | $178.61 | 2024-2025 | Izervay |
| Sight Sciences, INC. | $174.93 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Mallinckrodt Enterprises LLC | $156.67 | 2019 | |
| Abbvie INC. | $143.13 | 2023-2025 | |
| Omeros Corporation | $120.73 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $105.32 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $87.73 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $71.62 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $52.76 | 2021 | |
| Genentech USA, INC. | $47.36 | 2022-2024 | Vabysmo |
| Argenx US, INC. | $39.91 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Galderma Laboratories, L.P. | $30.00 | 2025 | |
| Apellis Pharmaceuticals, INC. | $23.77 | 2024 | Syfovre |
| Eyepoint US, INC. | $22.86 | 2022 | |
| Spark Therapeutics, INC. | $15.11 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.15 | 2019 | |
| Alimera Sciences, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rheeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.